Whiteoak Capital Pharma and Healthcare Fund - Regular Plan - Growth
WhiteOak Capital Asset Management Limited
₹16.15 (+0.60%)
NAV as of 9 Oct 2026
Minimum Investment: ₹500
Return
16.19% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.37%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹500
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,191
Invested ₹1,000
▲+19.05%1 year
₹1,162
Invested ₹1,000
▲+16.19%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +16.19% | — | — | — |
| Cumulative returns (%) | +16.19% | — | — | — |
Fund Manager
| Manager | Ashish Agrawal |
|---|---|
| Role | Manager |
| Manager Tenure | 1.73 yrs |
About Fund
| Date of Incorporation | 6 Feb 2024 |
|---|---|
| Fund House | WhiteOak Capital Asset Management Limited |
| Custodian | Deutsche Bank AG |
| Registrar / Transfer Agent | WhiteOak Capital Asset Management Limited |
| Address | 1 Great Winchester Street |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Divi's Laboratories Ltd | 8.45% |
| Sun Pharmaceuticals Industries Ltd | 7.40% |
| J.B. Chemicals & Pharmaceuticals Ltd | 6.94% |
| Torrent Pharmaceuticals Ltd | 6.78% |
| Lupin Ltd | 5.77% |
| Apollo Hospitals Enterprise Ltd | 4.73% |
| Laurus Labs Ltd | 3.78% |
| Fortis Healthcare Ltd | 3.62% |
| Glenmark Pharmaceuticals Ltd | 3.41% |
| Alkem Laboratories Ltd | 3.36% |
| Sai Life Sciences Ltd | 3.32% |
| Krishna Institute of Medical Sciences Ltd | 3.30% |
| Cipla Ltd | 3.25% |
| Anthem Biosciences Ltd | 3.25% |
| Max Healthcare Institute Ltd Ordinary Shares | 3.05% |
| Zydus Lifesciences Ltd | 2.94% |
| Neuland Laboratories Ltd | 2.88% |
| Aurobindo Pharma Ltd | 2.69% |
| Ipca Laboratories Ltd | 2.66% |
| Vijaya Diagnostic Centre Ltd | 2.61% |
Investment Strategy
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Long term capital appreciation
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.